Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study
Authors:
- Christopher LucastiCLChristopher Lucasti
- Abel JasovichAJAbel Jasovich
- Obiamiwe UmehOUObiamiwe Umeh
- Joel JiangJJJoel Jiang
- Koné KanigaKKKoné Kaniga
- Ian FriedlandIFIan Friedland
- 1 May 2008
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 30 (5) , 868-883
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Empiric treatment options in the management of complicated intra-abdominal infections.Cleveland Clinic Journal of Medicine, 2007
- Potency of Carbapenems for the Prevention of Carbapenem-Resistant Mutants of Pseudomonas aeruginosaThe Journal of Antibiotics, 2006
- Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)Clinical Microbiology and Infection, 2005
- In Vitro Activities of Doripenem and Comparator Agents against 364 Anaerobic Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Empiric Treatment of Nosocomial Intra-Abdominal Infections: A Focus on the CarbapenemsSurgical Infections, 2005
- Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanismsDiagnostic Microbiology and Infectious Disease, 2005
- ErtapenemDrugs, 2005
- Neurotoxicity of Carbapenem AntibacterialsDrug Safety, 1996
- Imipenem/cilastatin therapy of infections in cancer patientsCancer, 1987
- Imipenem/Cilastatin in the Treatment of Intraabdominal Infections: A Review of Worldwide ExperienceClinical Infectious Diseases, 1985